Lv51
850 积分 2022-08-16 加入
Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization
1小时前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
3天前
已完结
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer
4天前
已完结
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer
5天前
已完结
Feasibility and safety of perioperative entrectinib in a patient with ROS1-positive locally advanced NSCLC: A case report
12天前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
16天前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
16天前
已完结
The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study
17天前
已关闭
Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study
17天前
已完结
Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study
18天前
已完结
皖公网安备34019202002308
